Sign In
Buy AKBA
$0.84
-0.0659 (-7.24%)
At Close: Aug 10, 2026
Is the Options Market Predicting a Spike in Akebia Therapeutics Stock?
10:01am, Tuesday, 17'th Mar 2026
Investors need to pay close attention to AKBA stock based on the movements in the options market lately.
Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript
05:58pm, Monday, 09'th Mar 2026
Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
08:00am, Tuesday, 03'rd Mar 2026
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 02'nd Mar 2026
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease
Akebia Therapeutics Q4 Earnings Call Highlights
02:36am, Sunday, 01'st Mar 2026
Akebia Therapeutics (NASDAQ: AKBA) executives used the company's fourth-quarter 2025 earnings call to review the first full year of Vafseo's U.S. launch, discuss efforts to build clinical and economic
Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript
11:27am, Thursday, 26'th Feb 2026
Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
07:00am, Thursday, 26'th Feb 2026
Q4 2025 net product revenues of $54.3 million ; 2025 full-year net product revenues of $227.3 million , representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
08:00am, Thursday, 19'th Feb 2026
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended Decembe
Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
04:57pm, Friday, 13'th Feb 2026
Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
08:00am, Wednesday, 04'th Feb 2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 02'nd Feb 2026
CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives $6.00 Consensus Price Target from Analysts
01:26am, Monday, 02'nd Feb 2026
Shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat Ratings reports. O
Vivos Therapeutics (NASDAQ:VVOS) and Akebia Therapeutics (NASDAQ:AKBA) Head to Head Contrast
06:13am, Tuesday, 20'th Jan 2026
Akebia Therapeutics (NASDAQ: AKBA - Get Free Report) and Vivos Therapeutics (NASDAQ: VVOS - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contras
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts
01:21pm, Tuesday, 13'th Jan 2026
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
08:00am, Monday, 12'th Jan 2026
Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in Praliciguat Phase 2 clinical trial studying focal segmental glomer
